// App-Quantinova.ai

2003 : Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

Researchers

Presenter

  • Nizar J. Bahlis

Principal Investigators

  • Karen Valentine

  • Deirdre A. Jenkins

  • Carolyn J Owen

  • Mona Shafey

  • Peter Duggan

  • Douglas A. Stewart

Medical Centers

  • Medicine and Oncology, University of Calgary,

  • Medicine and Oncology, University of Calgary, Calgary, AB, Canada

  • University of Calgary, Southern Alberta Cancer Research Institute, Calgary, AB, Canada

  • University of Calgary, Southern Alberta Cancer Research Institute, Calgary, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Peripheral T-cell lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • B cell lymphomas

  • T-cell lymphoma

  • Encephalopathy

  • CNS lymphoma

  • Lymphomas

Biomarkers

  • Lactate dehydrogenase

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Methotrexate

  • Cytarabine liposomal

  • Melphalan

  • Rituximab

  • Busulfan

  • Thiotepa

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved